Class Action Lawsuit Overview
PepGen Inc. (NASDAQ: PEPG) faces a class action lawsuit that is crucial for investors who purchased shares during the specified period. The case revolves around serious allegations against the company regarding misleading statements about their product candidate. Understanding the implications of this lawsuit is vital for shareholders.
Allegations Against PepGen Inc.
The lawsuit centers on multiple accusations directed at PepGen's practices. Investors have raised concerns that the company provided materially false and misleading information regarding their lead product candidate, PGN-EDO51. It is claimed that the product was represented as being more effective and safer than it truly was.
Furthermore, the allegations extend to the CONNECT2 study in which PGN-EDO51 was involved. Reports suggest that the clinical trial was not only potentially dangerous but also lacked the necessary standards for FDA approval. Such assertions put the company's credibility in jeopardy, as it was propagated that PGN-EDO51's prospects had been inaccurately inflated.
Deadlines for Class Action Registration
Investors interested in joining the class action should be aware of important deadlines. Shareholders must register their information by August 8, 2025. Delaying may limit their ability to recover potential losses associated with their investment in PepGen.
Those who purchased shares of PEPG during the confirmed class period from March 7, 2024, to March 3, 2025, are requested to take action promptly. Registration is crucial to ensure eligibility for any recovery as part of this legal action.
Next Steps After Registration
Upon registering, shareholders will have access to a portfolio monitoring system that provides ongoing updates about the case. This system ensures that investors remain informed about the progress and key developments throughout the lawsuit’s lifecycle.
The firm encouraging this registration is committed to protecting investor rights, emphasizing that no financial obligation exists for those who choose to participate. This effort aims to ensure that shareholders stay informed and supported as the case unfolds.
Why Choose The Gross Law Firm?
The Gross Law Firm, which spearheads this class action, is renowned for its dedication to safeguarding investors from deceptive practices. Their commitment extends to advocating for proper corporate behavior and transparency in business operations.
With a history of representing investors, The Gross Law Firm emphasizes the importance of responsible business conduct. They work tirelessly to ensure that companies face accountability for actions that lead to financial damages for investors, such as misleading statements or information omissions.
Contact Information for Interested Shareholders
Interested investors can reach out to The Gross Law Firm to learn more about the class action. The firm is based at 15 West 38th Street, 12th floor, New York, NY 10018, and is equipped to assist those affected.
By contacting The Gross Law Firm, investors can obtain relevant details about the class action, registration procedures, and any other inquiries related to their investments in PepGen Inc.
Frequently Asked Questions
What is the deadline to register for the class action?
The deadline to register for the class action against PepGen Inc. is August 8, 2025.
What are the main allegations against PepGen Inc.?
PepGen Inc. is accused of issuing false statements regarding the effectiveness and safety of its product candidate, PGN-EDO51, and the adequacy of its clinical trials for FDA approval.
How can I register for the class action?
Shareholders can register their information with The Gross Law Firm, specifically those who purchased shares between March 7, 2024, and March 3, 2025.
Is there a cost to participate in the class action?
No, there is no cost or obligation for shareholders to participate in the class action.
Why should I choose The Gross Law Firm?
The Gross Law Firm is a nationally recognized firm with a strong commitment to protecting investors' rights and ensuring corporate accountability.
